Safety of Insulin Glulisine when Given by Continuous Subcutaneous Infusion Using an External Pump in Patients with Type 1 Diabetes

Abstract

This twelve-week, European, multicenter, controlled, open-label, randomized (1 : 1), parallel-group trial compared the safety of insulin glulisine with insulin aspart used in continuous subcutaneous insulin infusion. Patients with type 1 diabetes (n = 59) and continuous subcutaneous insulin infusion experience (mean values: HbA_1c 6.9 % [insulin glulisine: 6.8 % vs. insulin aspart: 7.1 %]; age 45.8 years; body mass index 26.0 kg/m²) were enrolled. HbA_1c levels at endpoint (insulin glulisine: 7.0 % vs. insulin aspart: 7.2 %), daily insulin doses, blood glucose profiles and adverse event rates were similar in both groups. The median (minimum-maximum) catheter occlusion rate was low for insulin glulisine and insulin aspart (0 [0 - 0.7] vs. 0 [0 - 1.1] occlusions/month. Unexplained hyperglycemia occurred in six insulin glulisine-treated patients and twelve insulin aspart-treated patients. Patients were expected to change their catheters every 2 days (15 changes/month); the catheter change rate was similar for insulin glulisine and insulin aspart (14.1 vs. 14.8 changes/month). The frequency of infusion site reactions and hypoglycemia, and the time between catheter changes were similar for both insulin forms. Diabetic ketoacidosis was not reported. This study supports the safety of insulin glulisine in continuous subcutaneous insulin infusion administered via an external pump in type 1 diabetes.

Key words

Insulin aspart - hypoglycemia - hyperglycemia - catheter occlusion - adverse events

References

• 1 Renner R, Pfutzner A, Trautmann M, Harzer O, Sauter K, Landgraf R. Use of insulin lispro in continuous subcutaneous insulin infusion treatment. Results of a multicenter trial. German Humalog-CSII Study Group.  Diabetes Care. 1999;  22 784-788
• 2 Bode B, Weinstein R, Bell D. Comparison of insulin aspart with buffered regular insulin and insulin lispro for continuous subcutaneous insulin infusion.  Diabetes Care. 2002;  25 439-444
• 3 Bode B. Insulin aspart efficacy and safety compared to buffered regular insulin and insulin lispro for continuous subcutaneous insulin infusion.  Diabetes. 2001;  50 A106
• 4 Zinman B, Tildeslex H, Chaisson J-L. Insulin lispro in CSII: results of a double-blind crossover study.  Diabetes. 1997;  46 440-443
• 5 Garg S, Andersen J, Gerard L. Impact of insulin lispro on HbA1c values in insulin pump users.  Diabetes Obesity Metab. 2000;  2 307-311
• 6 Heinemann L, Weyer C, Rauhaus M, Heinrichs S, Heise T. Variability of the metabolic effect of soluble insulin and the rapid-acting insulin analog insulin aspart.  Diabetes Care. 1998;  21 1910-1914
• 7 Colquitt J, Royle P, Waugh N. Are analogue insulins better than soluble in continuous subcutaneous insulin infusion? Results of a meta-analysis.  Diabet Med. 2003;  20 863-866
• 8 Hanaire-Broutin H, Melki V, Bessieres-Lacombe S, Tauber J P. Comparison of continuous subcutaneous insulin infusion and multiple daily injection regimens using insulin lispro in type 1 diabetic patients on intensified treatment: a randomized study. The Study Group for the Development of Pump Therapy in Diabetes.  Diabetes Care. 2000;  23 1232-1235
• 9 Pickup J, Keen H. Continuous subcutaneous insulin infusion in type 1 diabetes.  BMJ. 2001;  322 1262-1263
• 10 Becker R, Frick A, Wessels D, Scholtz H. Evaluation of the pharmacodynamic and pharmacokinetic profiles of insulin glulisine - a novel, rapid-acting, human insulin analogue.  Diabetologia. 2003;  46 Abstract 775
• 11 Frick A, Becker R, Wessels D, Scholtz H. Pharmacokinetic and glucodynamic profiles of insulin glulisine: an evaluation following subcutaneous administration at various injection sites.  Diabetologia. 2003;  46 Abstract 776
• 12 Melki V, Renard E, Lassmann-Vague V, Boivin S, Guerci B, Hanaire-Broutin H, Bringer J, Belicar P, Jeandidier N, Meyer L, Blin P, Augendre-Ferrante B, Tauber J P. Improvement of HbA1c and blood glucose stability in IDDM patients treated with lispro insulin analog in external pumps.  Diabetes Care. 1998;  21 977-982
• 13 The Diabetes Control and Complications Trial Research Group, DCCT . The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus.  N Engl J Med. 1993;  329 977-986
• 14 Guerci B, Meyer L, Salle A, Charrie A, Dousset B, Ziegler O, Drouin P. Comparison of metabolic deterioration between insulin analog and regular insulin after a 5-hour interruption of a continuous subcutaneous insulin infusion in type 1 diabetic patients.  J Clin Endocrinol Metab. 1999;  84 2673-2678
• 15 Bode B W, Strange P. Efficacy, safety, and pump compatibility of insulin aspart used in continuous subcutaneous insulin infusion therapy in patients with type 1 diabetes.  Diabetes Care. 2001;  24 69-72